Evidence map›Paper›PMID 12569372›Full record

ArticleOncogene2003

ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells.

Ming-Shyue Lee, Tsukasa Igawa, Ta-Chun Yuan, Xiu-Qing Zhang, Fen-Fen Lin, Ming-Fong Lin

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Article
  3. Targeting treatment options for castration-resistant prostate cancer.American journal of clinical and experimental urology · 2021
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Human prostatic acid phosphatase: structure, function and regulation.International journal of molecular sciences · 2013
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ming-Shyue LeeDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha 68198, USA.
Tsukasa Igawa
Ta-Chun Yuan
Xiu-Qing Zhang
Fen-Fen Lin
Ming-Fong Lin
University of Nebraska Medical Center · US

Funding

SIGNALING IN ANDROGEN REFRACTORY PROSTATE CANCERR01CA088184 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI LIN, MING-FONG · 2000 to 2010
$2.6M
NCI NIH HHS CA88184
6 · The paper itself

Abstract

The expression and secretion of prostate-specific antigen (PSA) are regulated by androgens in normal prostate secretory epithelial cells. In prostate cancer patients, the serum PSA level is usually elevated and cancer cells are initially responsive to androgens. However, those cancer cells become androgen-independent after androgen ablation therapy. In hormone-refractory cancer patients, even in an androgen-deprived environment, the circulation level of PSA rebounds and is constitutively elevated through a yet unknown mechanism. Tyrosine phosphorylation of ErbB-2 is involved in regulating the androgen-responsive phenotype of prostate cancer cells, and it is at least partly regulated by the cellular form of prostatic acid phosphatase (PAcP), a prostate-unique protein tyrosine phosphatase. We investigated the ErbB-2 signal pathway in androgen-independent PSA secretion. LNCaP C-81 cells, which are androgen-independent LNCaP cells lacking endogenous PAcP expression with a hypertyrosine phosphorylated ErbB-2, secreted a higher level of PSA in conditioned media than did androgen-sensitive LNCaP C-33 parental cells. A restored expression of cellular PAcP in C-81 cells was concurrent with a decrease in tyrophosphorylation of ErbB-2 and reduction of PSA secretion. Moreover, transient transfection of C-33 cells with the wild-type ErbB-2 or a constitutively active mutant of MEK1 cDNA resulted in an increased level of secreted PSA. The elevation of secreted PSA level by the forced expression of ErbB-2 was inhibited by an MEK inhibitor, PD98059. In C-81 cells, the expression of a dominant negative mutant of ErbB-2 reduced the secreted level of PSA. The inhibition of ErbB-2 or mitogen-activated protein (MAP) kinases by specific inhibitors AG879, AG825, or PD98059 led to a decrease in PSA secretion. Taken together, our data clearly indicate that the ErbB-2 signal pathway via MAP kinases (ERK1/2) is involved in regulating the secretion of PSA by androgen-independent human prostate cancer LNCaP C-81 cells in an androgen-depleted environment.

Indexed as

MAP Kinase Kinase Kinase 1Acid PhosphataseAndrogensCell DivisionCulture Media, ConditionedErb-b2 Receptor Tyrosine KinasesHumansMaleMitogen-Activated Protein KinasesProstate-Specific AntigenProstatic NeoplasmsProtein Serine-Threonine KinasesProtein Tyrosine PhosphatasesSignal TransductionTumor Cells, CulturedUp-RegulationAcid PhosphataseAndrogensCulture Media, ConditionedErb-b2 Receptor Tyrosine KinasesMAP3K1 protein, humanMAP Kinase Kinase Kinase 1Mitogen-Activated Protein KinasesProstate-Specific Antigenprostatic acid phosphataseProtein Serine-Threonine KinasesProtein Tyrosine Phosphatases

Identifiers

PMID12569372
OpenAlexW1967839028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.